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Abstract Phosphatases converting 3P-phosphoadenosine 5P-
phosphate (PAP) into adenosine 5P-phosphate are of fundamental
importance in living cells as the accumulation of PAP is toxic to
several cellular systems. These enzymes are lithium-sensitive and
we have characterized a human PAP phosphatase as a potential
target of lithium therapy. A cDNA encoding a human enzyme
was identified by data base screening, expressed in Escherichia
coli and the 33 kDa protein purified to homogeneity. The enzyme
exhibits high affinity for PAP (Km 61 WM) and is sensitive to
subtherapeutic concentrations of lithium (IC50 = 0.3 mM). The
human enzyme also hydrolyzes inositol-1,4-bisphosphate with
high affinity (Km = 0.4 WM), therefore it can be considered as a
dual specificity enzyme with high affinity (WM range) for both
PAP and inositol-1,4-bisphosphate. Hydrolysis of inositol-1,4-
bisphosphate was also inhibited by lithium (IC50 = 0.6 mM).
Thus, we present experimental evidence for a novel target of
lithium therapy, which could explain some of the side effects of
this therapy.
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1. Introduction
3P(2P)-Phosphoadenosine 5P-phosphate (PAP) phosphatases
(EC 3.1.3.7) [1] are enzymes present in bacteria, yeast, plant
and animal cells [2^6]. They constitute a branch of a super-
family of magnesium-dependent lithium-sensitive phospha-
tases, which also includes fructose-1,6-bisphosphate 1-phos-
phatase, inositol-polyphosphate 1-phosphatase and inositol
monophosphatase enzymes [7,8]. PAP phosphatases speci¢-
cally catalyze the hydrolysis of the 3P-phosphate from PAP,
thereby recycling PAP to adenosine 5P-phosphate (AMP) and
inorganic phosphate [3]. PAP is a potent inhibitor of a variety
of enzymes that use 3P-phosphoadenosine 5P-phosphosulfate
(PAPS) as cosubstrate, mainly PAPS reductases and sulfo-
transferases [9^13]. PAP acts as a competitive inhibitor with
respect to PAPS because of their close structural similarity.
Additionally, PAP mimics the monomers of a polyribonucleo-
tide chain and this fact might explain the observed toxic e¡ect
of PAP on RNA processing enzymes [14]. Therefore, in order
to prevent the inhibition of both PAPS-utilizing and RNA
processing enzymes, the activity of PAP phosphatases is re-
quired [4,15]. Thus, PAP phosphatases play a crucial role in
the maintenance of sulfation reactions, the assimilation of
inorganic sulfate in Saccharomyces cerevisiae and probably
in Escherichia coli, as well as in RNA processing metabolism
[16].
The S. cerevisiae Hal2 protein was the ¢rst PAP phospha-
tase to be biochemically characterized [3]. The PAP phospha-
tase activity of Hal2p is crucial for the function of yeast PAPS
reductase, which is a key enzyme in the yeast sulfate assim-
ilation pathway that leads to the synthesis of methionine [17].
Indeed, hal2 cells are auxotrophic for methionine [17,18]. We
took advantage of this phenotype to clone a rat PAP phos-
phatase (RnPIP) by functional complementation of the auxo-
trophy for methionine of hal2 cells with a rat cDNA library
[5]. A mouse homologue of RnPIP was independently re-
ported [6]. In spite of the high sequence identity of the mouse
and rat enzymes, there exists a discrepancy regarding the sub-
strate speci¢city of the two mammalian enzymes investigated.
RnPIP exhibits high a⁄nity both for PAP and inositol-1,4-
bisphosphate [5], whereas for the mouse homologue only PAP
can be considered a physiological substrate [6]. The mamma-
lian PAP phosphatases are lithium-sensitive enzymes [5,6],
and therefore, the human enzyme could represent a novel
target of lithium therapy, in addition to the well-known ino-
sitol phosphatases [19]. Therefore, in the present work, we
identi¢ed and characterized a human PAP phosphatase. The
human enzyme shows a dual speci¢city, acting both on PAP
and inositol-1,4-bisphosphate, and it is very sensitive to lith-
ium. Finally, we discuss that, in contrast to what has been
proposed [6], methionine supplementation in lithium therapy
cannot overcome lithium toxicity (as occurs in yeast) [18] be-
cause of the dramatic di¡erences in methionine metabolism
between yeast and humans.
2. Materials and methods
2.1. Chemicals
All non-radioactive organic compounds were obtained from Sigma.
Radioactive compounds were purchased from NEN Life Science
Products.
2.2. Expression of HsPIP in E. coli and protein puri¢cation
The open reading frame (ORF) of HsPIP was ampli¢ed by PCR
using the following primers: ORF5P : 5P-ATT TAT GAA TTC ATG
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GCT TCC AGT AAC ACT-3P and ORF3P : 5P-ATT TAT CTC GAG
TTA AGG AAC AAG TGC ATT-3P (restriction sites are in bold face
and start and stop codons are italicized). The resulting product was
digested with EcoRI and XhoI and ligated into the pET-28a histidine-
tagged expression vector (Novagen). The HsPIP/pET-28a vector was
con¢rmed by sequencing, transformed into the E. coli strain BL21
(DE3) and the protein was expressed and puri¢ed using Ni2 chro-
matography, as recommended by the manufacturer.
2.3. Colorimetric enzyme assay
PAP phosphatase and inositol-polyphosphate 1-phosphatase colori-
metric assays were basically performed as described [3]. Brie£y, a
standard assay was conducted in a 100 Wl mixture containing 50
mM Tris^HCl pH 7.5, 1 mM magnesium chloride, and the indicated
amount of protein and substrate. After 30 min incubation at 30‡C, the
inorganic phosphate released was quanti¢ed by the malachite green
method as described [20]. Under these conditions, the enzyme activity
was linear with protein quantity (up to 3 Wg) and reaction time (up to
1 h).
2.4. High-pressure liquid chromatography (HPLC) analysis of the
hydrolysis of PAP and [3H]inositol-1,4-bisphosphate
Analysis of reaction products and determination of Km values for
PAP and inositol-1,4-bisphosphate hydrolysis were carried out by
HPLC. In the case of PAP, the conditions for the HPLC analysis
and detection by ultraviolet absorption of the reaction product have
been described previously [3]. Inositol-1,4-bisphosphate hydrolysis
was assayed in a reaction mixture containing 0.2 M potassium N,N-
bis(2-hydroxyethyl)glycine (bicine) (pH 8.0), 1 mM MgCl2, and the
indicated amount of inositol-1,4-bisphosphate and/or [3H]inositol-1,4-
bisphosphate (10 Ci/mmol). At the indicated time, 10 Wl of reaction
mixture was injected into a 4.6U10 mm Guard Cartridge 10 Wm SAX
column linked to a 4.6U250 mm Partisil 10 Wm SAX column (pS
Phase Sep), equilibrated in Milli Q water and maintained at 22‡C
with a £ow rate of 1 ml/min. Inositol phosphates were eluted with a
linear gradient of (NH4)H2PO4, pH 3.7, according to [21].
[3H]Inositol phosphates were detected with a RadioFlow detector
LB509 (EGG Berthold) using Opti£ow as scintillation cocktail at a
£ow rate of 3 ml/min.
3. Results
3.1. Cloning of HsPIP
RnPIP is a rat enzyme representative of the animal gene
family of PAP phosphatases [5,6]. Expressed sequence tags
(ESTs) encoding proteins with high sequence identity to
RnPIP are present in the nematode Caenorhabditis elegans,
Drosophila and humans. We have screened the human data
base of ESTs to obtain a candidate cDNA encoding the hu-
man version of RnPIP. Data base screening identi¢ed a
cDNA from a human germinal center B-cells library
(I.M.A.G.E. Consortium Clone ID 1240760) [22] with 90%
sequence identity to RnPIP. Sequencing of this cDNA reveals
a 927 bp ORF that putatively encodes a protein of 308 amino
acid residues with a calculated molecular mass of 33.4 kDa
(Fig. 1). We named this gene HsPIP and the corresponding
protein HsPIP (see below).
3.2. Puri¢cation of His-tagged HsPIP protein and biochemical
characterization
The puri¢cation of HsPIP was carried out using an NH2-
Fig. 1. The nucleotide sequence and the deduced amino acid sequence of the HsPIP cDNA. The amino acid sequence of the putative coding
region is shown below the nucleotide sequence. The stop codon in frame with the ORF is indicated with an asterisk. The three conserved re-
gions [8] involved in the coordination of phosphate and metal ions and nucleophilic water activation are indicated in bold face and underlined.
The nucleotide sequence of the HsPIP gene has been deposited at the GenBank/EBI data base under the accession number AJ249339. The
HsPIP cDNA clone was provided by the HGMP Resource Centre and it corresponds to the I.M.A.G.E. Consortium Clone ID 1240760.
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terminal histidine-tagged fusion protein prepared as described
in Section 2. Sodium dodecyl sulfate^polyacrylamide gel elec-
trophoresis (SDS^PAGE) analysis demonstrates that the fu-
sion protein displays the expected apparent molecular mass of
33 kDa and is readily puri¢ed to homogeneity by Ni2 chro-
matography (Fig. 2). The substrate speci¢city of the enzyme
was determined in vitro by quantitating the release of inor-
ganic phosphate. HsPIP catalyzes the dephosphorylation of
both PAP and inositol-1,4-bisphosphate (Table 1), but not
of the structurally related compounds adenosine 3P-phosphate
(3P-AMP), inositol-1-phosphate and inositol-1,4,5-triphos-
phate (data not shown). The speci¢c activity for PAP is ap-
proximately 5-fold higher than for inositol-1,4-bisphosphate
(Table 1). Next, we examined the cation sensitivity of HsPIP.
The phosphatase activity of HsPIP was strictly Mg2-depen-
dent, with an optimal concentration of 1 mM (data not
shown). The concentration of Li that decreased the activity
of the enzyme by 50% relative to a reaction without Li (IC50)
was estimated at a substrate concentration of 0.1 mM PAP or
0.1 mM inositol-1,4-bisphosphate (Fig. 3). As this value that
represents a saturating concentration of substrate (see below),
the IC50 is very close to the Ki [23]. As expected, HsPIP was
very sensitive to inhibition by Li (IC50 = 0.3 mM for hydro-
lysis of PAP; IC50 = 0.6 mM for hydrolysis of inositol-1,4-bis-
phosphate). The e¡ect of Li is unique among the group of
monovalent cations and HsPIP was not a¡ected by high Na
concentration (up to 200 mM).
3.3. Analysis of reaction products and determination of
Km values by HPLC
To determine the position of the phosphate liberated from
PAP and inositol-1,4-bisphosphate, we have analyzed the re-
action products of either PAP or inositol-1,4-bisphosphate
hydrolysis by HPLC. HsPIP converts 3P-PAP to 5P-AMP by
hydrolysis of the 3P-phosphate (Fig. 4A). 2P-PAP was also
hydrolyzed by HsPIP, although with a reduced e⁄ciency
(30% with respect to 3P-PAP). Inositol-1,4-bisphosphate was
converted to inositol-4-phosphate (Fig. 4B) by hydrolysis of
the 1P-phosphate. To measure the a⁄nity of HsPIP for these
substrates, we determined the Km values for PAP and inositol-
1,4-bisphosphate (Table 1). The apparent Km for tritium-la-
beled inositol-1,4-bisphosphate was 0.4 WM (Fig. 5). The Km
for PAP hydrolysis was below the detection limit (1 WM) of
the HPLC analysis. However, these data indicate a high af-
¢nity both for the PAP and inositol-1,4-bisphosphate sub-
strates.
4. Discussion
Enzyme nomenclature distinguishes 3P-5P-bisphosphate nu-
cleotidases (EC 3.1.3.7), i.e. PAP phosphatases, and inositol-
1,4-bisphosphate 1-phosphatase (EC 3.1.3.57). However, the
mammalian PAP phosphatases HsPIP and the previously de-
scribed rat homologue RnPIP [5] act with high a⁄nity on
both PAP and inositol-1,4-bisphosphate, and di¡er in this
respect from the PAP phosphatases of yeast and plants
[4,24,25]. We propose that the mammalian genes encode a
novel class of true dual speci¢city enzymes and thus should
receive a separate EC entry. The de¢ning feature of this en-
zyme family is a high a⁄nity for both substrates, as opposed
to the Arabidopsis and yeast PAP phosphatases, which only
show high a⁄nity for PAP and Km values for inositol-1,4-
bisphosphate in the millimolar range [4,24,25]. Therefore, in
addition to a role as PAP detoxifying enzymes, the mamma-
lian enzymes could play a role in inositol recycling and phos-
phoinositide metabolism. Future studies should investigate the
relative contribution of HsPIP and inositol-polyphosphate
Fig. 2. Puri¢cation of His-tagged HsPIP protein. Equivalent
amounts of crude extract from E. coli BL21 (DE3) cells expressing
the HsPIP histidine-tagged fusion protein (lane a) before IPTG in-
duction, (lane b) 3 h after induction and (lane c) 2 Wg of puri¢ed
protein after metal chelation chromatography. Samples were sepa-
rated by SDS^PAGE and proteins visualized with Coomassie blue.
Relative positions of the molecular weight markers are shown on
the left.
Table 1
Biochemical characterization of HsPIP
Substrates Km Vmax
PAP 6 1 1.1
Inositol-1,4-bisphosphate 0.4 0.2
The Km value for inositol-1,4-bisphosphate of HsPIP is taken from
Fig. 5. The Km value for PAP was below the detection limit (1 WM)
of the HPLC analysis. The Km values are in WM. The Vmax values
are expressed as Wmol Pi/min/mg. The results are the average of two
independent experiments, each performed in duplicate. S.D.s were
less than 5%.
Fig. 3. E¡ect of lithium on the hydrolysis of PAP and inositol-1,4-
bisphosphate. Increasing amounts of lithium were used in a stan-
dard phosphatase reaction with 1 Wg of HsPIP and 0.1 mM PAP
(black circle) or inositol-1,4-bisphosphate (black square) as sub-
strate. The results are expressed as percent activity observed in the
absence of lithium and are the average of at least two independent
experiments, each performed in duplicate. S.D.s were less than 5%.
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1-phosphatase to inositol-1,4-bisphosphate hydrolysis in dif-
ferent tissues.
Our results for the mammalian enzymes RnPIP [5] and
HsPIP (this work) di¡er substantially from those reported in
[6], as the Km for hydrolysis of inositol-1,4-bisphosphate was
at least 100-fold lower than the result reported for a murine
homologue [6]. Our biochemical characterization of the
HsPIP and RnPIP enzymes, together with a phylogenetic
study [5] of the family of magnesium-dependent lithium-sen-
sitive enzymes, points to a novel family of dual speci¢city
enzymes. Instead, the results reported for a murine homo-
logue indicate that PAP is the only physiological substrate
[6]. We suggest that the di¡erent methodology used for deter-
mination of the hydrolysis of inositol-1,4-bisphosphate might
account for this discrepancy, i.e. HPLC coupled to a Radio-
Flow detector ([5], this work) versus Dowex chromatography
[6]. We also disagree with the proposal of these authors for
co-administration of lithium with methionine in patients
treated for bipolar disorder. Based on the observation that
methionine supplementation can suppress lithium toxicity in
yeast [18], the authors [6] suggest a ‘similar’ strategy in hu-
mans. As we discuss below, this suggestion lacks a scienti¢c
basis and it could lead to an erroneous clinical practice.
In yeast, PAP is generated as a side product of PAPS re-
ductase, which is a key enzyme in the sulfate assimilation
pathway that leads to the synthesis of methionine [17]. PAP
accumulation has toxic e¡ects on the cell because it inhibits
PAPS reductase [10], and hence methionine biosynthesis, and
RNA processing enzymes [14]. Lithium inhibits the yeast PAP
phosphatase Hal2p [3], leading to the accumulation of PAP
[26] and therefore, the inhibition of methionine biosynthesis
and RNA processing. In the yeast context, it is obvious that
methionine supplementation can alleviate lithium toxicity be-
cause methionine biosynthesis is inhibited by PAP [3,26]. Ad-
ditionally, methionine supplementation prevents the accumu-
lation of PAP in yeast (and therefore, the inhibition of RNA
processing) by feed-back repression of the genes involved in
sulfate assimilation [27]. Sulfur metabolism in humans di¡ers
dramatically from yeast [28]. For instance, the predicted PAP
accumulation after lithium treatment in humans cannot have
a deleterious e¡ect on methionine biosynthesis (as in yeast)
because humans do not have such a pathway. Instead, me-
thionine is an essential amino acid that has to be ingested by a
proper diet [28]. In humans, PAP accumulation could have a
toxic e¡ect on RNA processing and PAPS-utilizing enzymes
[5], but there is no reason to hypothesize that methionine
Fig. 4. Identi¢cation by HPLC analysis of the reaction product of either PAP or inositol-1,4-bisphosphate hydrolysis catalyzed by HsPIP.
A: PAP hydrolysis. HsPIP (1 Wg) was incubated for 1 h at 30‡C in a bu¡er containing 0.2 M potassium bicine (pH 8.0), 1 mM MgCl2 and
1 mM PAP as substrate (mixture of 3P-PAP and 2P-PAP). The conditions of the HPLC analysis have previously been described [3]. 1, Stan-
dards of AMP, 3P-(2P)PAP and 3P-AMP were analyzed to determine the retention time. 2, Reaction mixture at time zero. 3, Reaction mixture
at 1 h. B: Inositol-1,4-bisphosphate hydrolysis. HsPIP (50 ng) was incubated for 5 min at 30‡C in a bu¡er containing 0.2 M potassium bicine
(pH 8.0), 1 mM MgCl2, 10 WM inositol-1,4-bisphosphate and 0.1 WM [3H]inositol-1,4-bisphosphate (10 Ci/mmol). The conditions of the HPLC
analysis are described in the text. 1, Standards of [3H]inositol-1-phosphate (1), [3H]inositol-4-phosphate (4) and [3H]inositol-1,4-bisphosphate
(1,4) were analyzed to determine the reaction time. 2, Reaction mixture at time zero. 3, Reaction mixture at 10 min.
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supplementation could prevent PAP accumulation and allevi-
ate lithium toxicity.
The human HsPIP phosphatase described in the present
work is a potential target of lithium therapy and it should
be considered in future pharmacological studies. In particular,
the predicted toxic accumulation of PAP during lithium treat-
ment could explain some of the side e¡ects of this therapy
whose positive e¡ects are probably related to the inhibition
of inositol monophosphatase in hyperactive brain zones [29].
HsPIP will also be inhibited by lithium in the same concen-
tration range as that associated with inositol monophospha-
tase inhibition. Therefore, the subsequent PAP accumulation
could have a variety of deleterious e¡ects because of the pleio-
tropic interference with RNA processing metabolism and
sulfation reactions.
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Fig. 5. Determination of the Km value for inositol-1,4-bisphosphate
hydrolysis. A: HPLC analysis was employed to measure reaction
rates at substrate concentrations of 111, 166 and 333 nM
[3H]inositol-1,4-bisphosphate (10 Ci/mmol). Analysis of the reaction
was performed by coupling the HPLC to a RadioFlow detector as
indicated in Section 2. B: Double reciprocal plot of initial rate ver-
sus concentration of [3H]inositol-1,4-bisphosphate. The graph repre-
sents the average of at least two independent experiments performed
in duplicate. Regression analysis of the data was performed using
the Kaleidagraph V.3.0.2 program (Abelbeck software). The regres-
sion coe⁄cient was 0.982.
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